SIST-TS CEN/TS 17626:2021
(Main)Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for human specimen - Isolated microbiome DNA
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes for human specimen - Isolated microbiome DNA
This document specifies requirements and recommendations for the pre-examination phase of human specimens, including saliva, skin, urine and stool, intended for microbiome DNA examination. The pre-examination phase includes but is not limited to specimen collection, handling, storage, processing and documentation.
This document is applicable to molecular in vitro diagnostic examinations performed by medical laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and manufacturers, biobanks, institutions and commercial organizations performing biomedical research, and regulatory authorities.
Different dedicated measures are taken for the pre-examination phase for infectious disease examination (eg. targeted pathogen identification). These are not described in this document.
Different dedicated measures are taken for the pre-examination phase of saliva for human genomic DNA examination. These are not described in this document but are covered in CEN WI00140116, Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for saliva — Isolated DNA.
NOTE International, national or regional regulations or requirements can also apply to specific topics covered in this document.
Molekularanalytische in-vitro-diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für menschliche Proben - Isolierte Mikrobiom-DNA
Dieses Dokument legt Anforderungen fest und gibt Empfehlungen für die präanalytische Untersuchungsphase von menschlichem Untersuchungsmaterial aus u. a. Stuhl, Speichel, Haut und dem Urogenitalbereich, das für die DNA Untersuchung des Mikrobioms vorgesehen ist. Die präanalytische Phase vor der Untersuchung umfasst unter anderem Entnahme, Handhabung, Transport, Lagerung und Verarbeitung des Untersuchungsmaterials, die Isolierung der DNA und die Dokumentation.
Dieses Dokument ist anwendbar auf molekulare in vitro-diagnostische Untersuchungen, die in medizinischen Laboratorien durchgeführt werden. Es ist außerdem für die Verwendung durch Kunden des Laboratoriums, Entwickler und Hersteller von In vitro-Diagnostika sowie Biobanken, Einrichtungen und kommerzielle Organisationen, die biomedizinische Forschungen durchführen, und Aufsichtsbehörden vorgesehen.
Für die präanalytischen Prozesse zur Untersuchung von Infektionskrankheiten (z. B. gezielte Erreger-identifizierung) und zur DNA Untersuchung des Mikrobioms aus Gewebe (z. B. Biopsien) sind andere zweckbestimmte Maßnahmen zu treffen. Diese liegen außerhalb des Anwendungsbereichs dieses Dokuments.
Für die präanalytischen Prozesse von Speichelproben zur genomischen Untersuchung menschlicher DNA sind andere zweckbestimmte Maßnahmen zu treffen. Diese werden nicht in diesem Dokument, sondern in CEN/TS 17305, Molekularanalytische in vitro-diagnostische Verfahren - Spezifikationen für präanalytische Prozesse für Speichel - Isolierte menschliche DNA, behandelt.
ANMERKUNG Für bestimmte Bereiche, die in diesem Dokument behandelt werden, können auch internationale, nationale oder regionale Bestimmungen oder Anforderungen gelten.
Analyses moléculaires de diagnostic in vitro - Spécifications relatives aux processus préanalytiques pour les échantillons humains - ADN du microbiote isolé
Molekularne diagnostične preiskave in vitro - Specifikacije za predpreiskovalne procese za vzorce človeškega tkiva - Izolirana mikrobiom DNA
General Information
Standards Content (Sample)
SLOVENSKI STANDARD
SIST-TS CEN/TS 17626:2021
01-julij-2021
Molekularne diagnostične preiskave in vitro - Specifikacije za predpreiskovalne
procese za vzorce človeškega tkiva - Izolirana mikrobiom DNA
Molecular in vitro diagnostic examinations - Specifications for pre-examination processes
for human specimen - Isolated microbiome DNA
Molekularanalytische in-vitro-diagnostische Verfahren - Spezifikationen für
präanalytische Prozesse für menschliche Proben - Isolierte Mikrobiom-DNA
Analyses moléculaires de diagnostic in vitro - Spécifications relatives aux processus
préanalytiques pour les échantillons humains - ADN du microbiote isolé
Ta slovenski standard je istoveten z: CEN/TS 17626:2021
ICS:
11.100.10 Diagnostični preskusni In vitro diagnostic test
sistemi in vitro systems
SIST-TS CEN/TS 17626:2021 en,fr,de
2003-01.Slovenski inštitut za standardizacijo. Razmnoževanje celote ali delov tega standarda ni dovoljeno.
---------------------- Page: 1 ----------------------
SIST-TS CEN/TS 17626:2021
---------------------- Page: 2 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626
TECHNICAL SPECIFICATION
SPÉCIFICATION TECHNIQUE
May 2021
TECHNISCHE SPEZIFIKATION
ICS 11.100.01
English Version
Molecular in vitro diagnostic examinations - Specifications
for pre-examination processes for human specimen -
Isolated microbiome DNA
Analyses moléculaires de diagnostic in vitro - Molekularanalytische in-vitro-diagnostische Verfahren
Spécifications relatives aux processus préanalytiques - Spezifikationen für präanalytische Prozesse für
pour les échantillons humains - ADN du microbiote menschliche Proben - Isolierte Mikrobiom-DNA
isolé
This Technical Specification (CEN/TS) was approved by CEN on 19 March 2021 for provisional application.
The period of validity of this CEN/TS is limited initially to three years. After two years the members of CEN will be requested to
submit their comments, particularly on the question whether the CEN/TS can be converted into a European Standard.
CEN members are required to announce the existence of this CEN/TS in the same way as for an EN and to make the CEN/TS
available promptly at national level in an appropriate form. It is permissible to keep conflicting national standards in force (in
parallel to the CEN/TS) until the final decision about the possible conversion of the CEN/TS into an EN is reached.
CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway,
Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and
United Kingdom.
EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG
CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels
© 2021 CEN All rights of exploitation in any form and by any means reserved Ref. No. CEN/TS 17626:2021 E
worldwide for CEN national Members.
---------------------- Page: 3 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
Contents Page
European foreword . 4
Introduction . 5
1 Scope . 6
2 Normative references . 6
3 Terms and definitions . 6
4 General considerations . 11
5 Outside the laboratory . 12
5.1 Specimen collection . 12
5.1.1 General . 12
5.1.2 Information about the patient/specimen donor . 13
5.1.3 Specific information about the patient/specimen donor . 13
5.1.4 Selection of specimen collection method and device(s) . 15
5.1.5 Specimen collection from the patient/specimen donor and specimen stabilization. 16
5.2 Specimen storage and transport . 18
5.2.1 General . 18
5.2.2 Using collection devices with stabilizers . 19
5.2.3 Using collection devices without stabilizers . 19
6 Inside the laboratory . 20
6.1 Specimen reception . 20
6.2 Processing of specimens . 20
6.3 Specimen storage before microbiome DNA isolation . 21
6.4 Isolation of microbiome DNA . 21
6.4.1 General . 21
6.4.2 Using a commercial kit . 22
6.4.3 Using a laboratory developed procedure . 23
6.5 Quantity and quality assessment of isolated microbiome DNA . 23
6.5.1 General . 23
6.5.2 Quantity assessment . 24
6.5.3 Quality assessment . 24
6.6 Storage of isolated microbiome DNA . 24
6.6.1 General . 24
6.6.2 Microbiome DNA isolated using a commercial kit . 25
6.6.3 Microbiome DNA isolated using a laboratory developed procedure . 25
Annex A (informative) Impact of various pre-analytical variables on microbiome DNA
quantity, quality and profile . 26
A.1 Introduction . 26
A.2 Result – Impact of specimen stabilization method on isolated microbiome DNA
quantity . 26
A.2.1 General . 26
A.2.2 Method . 26
A.2.3 Result/conclusion . 27
2
---------------------- Page: 4 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
A.3 Result – Impact of specimen to stabilizer mass/volume ratio on isolated microbiome
DNA quantity and quality. 28
A.3.1 General . 28
A.3.2 Method . 28
A.3.3 Result/conclusion . 28
A.4 Result – Impact of different microbiome DNA isolation methods on microbiome DNA
profile. 29
A.4.1 General . 29
A.4.2 Method . 29
A.4.3 Result/conclusion . 30
A.5 Results – Impact of stabilization status and storage of collected specimens/samples
on microbiome DNA profile . 31
A.5.1 General . 31
A.5.2 Method . 31
A.5.3 Result/conclusion . 32
Annex B (informative) Importance of using an in-process quality control material . 33
B.1 Introduction . 33
B.2 Results . 33
B.2.1 General . 33
B.2.2 Method . 33
B.2.3 Result . 35
B.3 Conclusions . 35
Bibliography . 36
3
---------------------- Page: 5 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
European foreword
This document (CEN/TS 17626:2021) has been prepared by Technical Committee CEN/TC 140 “In vitro
diagnostic medical devices”, the secretariat of which is held by DIN.
Attention is drawn to the possibility that some of the elements of this document may be the subject of
patent rights. CEN shall not be held responsible for identifying any or all such patent rights.
According to the CEN/CENELEC Internal Regulations, the national standards organisations of the
following countries are bound to announce this Technical Specification: Austria, Belgium, Bulgaria,
Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland,
Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Republic of
North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the
United Kingdom.
4
---------------------- Page: 6 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
Introduction
Molecular in vitro diagnostics has enabled significant progress in medicine. Further progress is
expected using new technologies analysing the microbiome (e.g. bacteria, fungi, viruses, yeasts,
archaea) in human specimens.
The human microbiome has come into focus in many medical disciplines such as gastroenterology,
dermatology, or gynaecology as a potential biomarker for diagnosis and management of diseases, and
even as a therapeutic agent. Technologies analysing microbiome DNA such as shotgun metagenome or
amplicon-based sequencing (e.g. 16S or 18S rRNA gene sequencing) have accelerated this process and
are being increasingly performed in research and clinical practice.
However, the human microbiome profile can change drastically during the pre-examination process,
which includes the specimen collection, transport, storage, and processing. These changes can, for
example, be due to contamination of specimens with microbial cells or DNA from other sources than the
sampling site or due to undesired growth and/or instability of individual microorganisms and viruses.
Consequently, this makes the outcome from diagnostics or research unreliable or even impossible
because the subsequent microbiome DNA examination might not determine the real situation in the
patient but an artificial profile generated during the pre-examination processes. Therefore, special
measures have to be taken to secure the stability of the microbiome profile.
Specimens for microbiome analysis are often collected by donors/patients. Therefore, dedicated
measures are needed for informing donors/patients about and preparing them for the collection,
storage and transport of specimens, and to check the compliance with the instructions, in order to
reduce specimen variability.
In addition, isolation of microbiome DNA, which is representative in composition of the in vivo
microbiome of the respective body site, is critical. This can be especially challenging e.g. due to different
lysis requirements of the microorganisms (e.g. Gram-negative versus Gram-positive bacteria, or versus
fungi) as well as inhibitory compounds (e.g. PCR inhibitors) in the specimen, which can impact the
examination if not removed during the DNA isolation. The presence of high amounts of human host
DNA, in addition to DNA introduced by reagents such as remnant plasmid DNA from generation of
recombinant enzymes and/or DNA isolation kits, can further impact the examination result.
Therefore, standardization of the entire pre-examination workflow from specimen collection to the
microbiome DNA examination is needed.
Studies have been undertaken to determine the important influencing factors. This document draws
upon such work to codify and standardize the steps for microbiome DNA examination in what is
referred to as the pre-examination phase.
In this document, the following verbal forms are used:
— “shall” indicates a requirement;
— “should” indicates a recommendation;
— “may” indicates a permission;
— “can” indicates a possibility or a capability.
5
---------------------- Page: 7 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
1 Scope
This document specifies requirements and gives recommendations for the pre-examination phase of
human specimens, such as stool, saliva, skin and urogenital specimens, intended for microbiome DNA
examination. The pre-examination phase includes but is not limited to specimen collection, handling,
transport, storage, processing, isolation of DNA, and documentation.
This document is applicable to molecular in vitro diagnostic examinations performed by medical
laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and
manufacturers, biobanks, institutions and commercial organizations performing biomedical research,
and regulatory authorities.
Different dedicated measures are taken for pre-examination processes for infectious disease
examination (e.g. targeted pathogen identification) and for microbiome DNA examination from tissue
(e.g. biopsies). These are outside of the scope of this document.
Different dedicated measures are taken for pre-examination processes for saliva for human genomic
DNA examination. These are not described in this document but are covered in CEN/TS 17305,
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for saliva —
Isolated DNA.
NOTE International, national or regional regulations or requirements can also apply to specific topics
covered in this document.
2 Normative references
The following documents are referred to in the text in such a way that some or all of their content
constitutes requirements of this document. For dated references, only the edition cited applies. For
undated references, the latest edition of the referenced document (including any amendments) applies.
EN ISO 15189, Medical laboratories — Requirements for quality and competence (ISO 15189)
ISO 15190, Medical laboratories — Requirements for safety
ISO/TS 20658, Medical laboratories — Requirements for collection, transport, receipt, and handling of
samples
3 Terms and definitions
For the purposes of this document, the terms and definitions given in EN ISO 15189 and the following
ones apply.
ISO and IEC maintain terminological databases for use in standardization at the following addresses:
— ISO Online browsing platform: available at https://www.iso.org/obp
— IEC Electropedia: available at https://www.electropedia.org/
6
---------------------- Page: 8 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
3.1
aliquot
portion of a larger amount of homogeneous material, assumed to be taken with negligible sampling
error
Note 1 to entry: The term is usually applied to fluids.
Note 2 to entry: The definition is derived from the Compendium of Chemical Terminology Gold Book.
International Union of Pure and Applied Chemistry. Version 2.3.3., 2014; the PAC, 1990,62,1193 (Nomenclature
for sampling in analytical chemistry (Recommendations 1990)) p. 1206; and the PAC, 1990,62,2167 (Glossary of
atmospheric chemistry terms (Recommendations 1990)) p. 2173
3.2
ambient temperature
unregulated temperature of the surrounding air
3.3
analyte
component represented in the name of a measurable quantity
[SOURCE: EN ISO 17511:2003]
3.4
deoxyribonucleic acid
DNA
polymer of deoxyribonucleotides occurring in a double-stranded (dsDNA) or single-stranded (ssDNA)
form
[SOURCE: EN ISO 22174:2005, 3.1.2]
3.5
deoxyribonuclease
DNase
enzyme that catalyzes the degradation of DNA [3.4] into smaller components
3.6
deviation
departure from an approved instruction, procedure and/or method
[SOURCE: EN ISO 15378:2017, 3.7.5 modified — The words “approved (3.7.1) standard operating
procedure (SOP) (3.7.10)” have been replaced by “instruction, procedure and/or method”.]
3.7
diagnosis
identification of a health or disease state from its signs and/or symptoms, where the diagnostic process
can involve examinations [3.8] and tests for classification of an individual's condition into separate and
distinct categories or subclasses that allow medical decisions about treatment and prognosis to be
made
7
---------------------- Page: 9 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
3.8
examination
analytical test
set of operations with the objective of determining the value or characteristics of a property
Note 1 to entry: Processes (i.e. set of operations) that start with the isolated analyte [3.3] and include all kinds
of parameter testing or chemical manipulation for quantitative or qualitative examination.
[SOURCE: EN ISO 15189:2012, 3.7, modified — The term and definition are used here without the
original Notes.]
3.9
examination manufacturer
analytical test manufacturer
entity that manufactures and/or produces the specific analytical test [3.8]
3.10
examination performance
analytical test performance
accuracy, precision, and sensitivity of a test to measure the analyte [3.3] of interest
Note 1 to entry: Other test performance characteristics such as robustness, repeatability can apply as well.
3.11
homogeneous
uniform in structure and composition
3.12
interfering substances
endogenous substances of a specimen [3.26]/sample [3.25] or exogenous substances (e.g. stabilization
reagent [3.28]) that can alter an examination result
3.13
laboratory developed procedure
modified commercially available in vitro diagnostic device or fully in house developed procedure
3.14
microbial biomass
measure of the mass (amount) of microbiome [3.15] in a specimen [3.26]/sample [3.25]
3.15
microbiome, human
entire community of all commensal, symbiotic and pathogenic microorganisms [3.18] and viruses inside
and on specific human body sites in a particular environment/habitat
[SOURCE: [1][2][3][4]]
3.16
microbiome DNA
microbial DNA
DNA [3.4] of the microorganisms [3.18] and DNA viruses comprising the human microbiome [3.15]
8
---------------------- Page: 10 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
3.17
microbiome DNA profile
microbial DNA profile
amounts of DNA molecules from the microbiome [3.15] that are present in a specimen [3.26]/sample
[3.25] and can be measured in the absence of any losses, inhibition or interference
3.18
microorganisms
entity of microscopic size, encompassing bacteria, archaea, single celled eukaryotes (incl. fungi,
protozoa), and phages
[SOURCE: [1][2]]
3.19
nonconformity
non-fulfillment of a requirement
[SOURCE: EN ISO 9000:2015, 3.6.9, modified — Note 1 to entry deleted.]
3.20
pre-examination processes
pre-analytical workflow
pre-examination phase
pre-analytical phase
processes that start, in chronological order, from the clinician’s request and include the examination
request, preparation and identification of the patient, collection of the specimen(s) [3.24],
transportation to and within the medical laboratory, isolation of analytes [3.3], and ends when the
examination [3.8] begins
Note 1 to entry: The pre-examination phase includes preparative processes that influence the outcome of the
intended examination.
[SOURCE: EN ISO 15189:2012, 3.15, modified — An additional term has been added, the words
“primary sample(s)” have been replaced by “specimen(s)” and more details have been included.]
3.21
primary collection device
tool specifically intended by a manufacturer to obtain or obtain and contain or obtain, contain and
preserve a specimen [3.26] from the donor/patient
[SOURCE: EN ISO 18113-1:2009, 3.55, Modified – Notes to entry have been deleted, “apparatus” has
been changed to “tool, “to obtain or obtain and contain” has been added, “for in vitro diagnostic
examination” has been deleted.]
3.22
secondary collection device
container into which the specimen [3.26] is transferred from or together with the primary collection
device [3.21]
9
---------------------- Page: 11 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
3.23
proficiency test
evaluation of participant performance against pre-established criteria by means of inter-laboratory
comparisons
[SOURCE: ISO/IEC 17043:2010, 3.7, modified — Term and definition are used here without the original
notes to entry.]
3.24
room temperature
for the purposes of this document, temperature in the range of 18 °C to 25 °C
Note 1 to entry: Local or national regulations can have different definitions.
3.25
sample
one or more parts taken from a specimen [3.26]
[SOURCE: EN ISO 15189:2012, 3.24, modified — The words “primary sample(s)” have been replaced by
“specimen(s)” and the example has been omitted.]
3.26
specimen
primary sample
discrete portion of a body fluid, breath, hair, stool, or biological material mechanically taken off body or
organ surfaces (e.g. by swabs, brushes, tapes, spatulas or blades) or tissue taken for examination of one
or more quantities or properties assumed to apply for the whole
[SOURCE: EN ISO 15189:2012, 3.16, modified — Notes to entry have been omitted.]
3.27
stability
ability of a specimen [3.26]/sample [3.25] material, when stored under specified conditions, to
maintain a stated property value within specified limits for a specified period of time
Note 1 to entry: The analyte for the purpose of this document is DNA.
[SOURCE: ISO Guide 30:2015, 2.1.15, modified — The words “reference material” have been replaced by
“specimen/sample material”.]
3.28
stabilizers
stabilization reagents
microbiome DNA stabilizers
compounds, solutions or mixtures that are designed to minimize changes of the microbiome DNA
profile [3.17] in a specimen [3.26] or sample [3.25] (by inhibition of undesired growth or decline of
microorganisms [3.18] and viruses, and/or of degradation and fragmentation of DNA [3.4])
3.29
storage
maintenance of biological material under conditions appropriate for intended use
10
---------------------- Page: 12 ----------------------
SIST-TS CEN/TS 17626:2021
CEN/TS 17626:2021 (E)
3.30
validation
confirmation, through the provision of objective evidence, that the requirements for a specific intended
use or application have been fulfilled
Note 1 to entry: The term “validated” is used to designate the corresponding status.
[SOURCE: ISO 9000:2015, 3.8.13, modified — Note 1 and 3 to entry have been omitted.]
3.31
verification
confirmation, through provision of objective evidence, that specified requirements have been fulfilled
Note 1 to entry: The term “verified” is used to designate the corresponding status.
Note 2 to entry: Confirmation can comprise activities such as:
— performing alternative calculations;
— comparing a new design specification with a similar proven design specification;
— undertaking tests and demonstrations; and
— reviewing documents prior to issue
[SOURCE: ISO 9000:2015, 3.8.12, modified — Note 1 and 2 to entry have been omitted. New Note 2 to
entry has been added.]
3.32
workflow
series of activities necessary to complete a task
[SOURCE: ISO 20166-1:2018, 3.30]
4 General considerations
For general statements on medical laboratory quality management systems and in particular on
specimen collection, reception and handling (including avoidance of cross contaminations), see
EN ISO 15189, EN ISO/IEC 17025 or EN ISO/IEC 17020. The requirements on laboratory equipment,
reagents, and consumables according to EN ISO 15189 shall be followed; EN ISO/IEC 17025 and
EN ISO/IEC 17020 can also apply.
All steps of the pre-examination, examination and post-examination processes (i.e. the entire workflow)
can influence the diagnosis or research study results.
Thus, this entire workflow shall be specified, verified and validated during the development of the
examination, including in vitro diagnostic (IVD) medical devices. This includes specifically all pre-
examination process steps such as the examination request, preparation and identification of the
patient, collection of the primary sample(s), transportation to and within the medical laboratory,
storage and isolation of analytes. This shall also include determination of and information on the
stability of the specimen within the timeframe between taking the specimen and its analysis and
storage conditions such as duration, temperature limits and freeze/thaw cycles.
The microbiome profile can change drastically during the pre-examination phase [5][6][27][28].
Microbiome composition and densities are influenced by lifestyle conditions
...
SLOVENSKI STANDARD
kSIST-TS FprCEN/TS 17626:2021
01-februar-2021
Molekularne diagnostične preiskave in vitro - Specifikacije za predpreiskovalne
procese za vzorce človeškega tkiva - Izolirana mikrobiom-DNA
Molecular in vitro diagnostic examinations — Specifications for pre-examination
processes for human specimen — Isolated microbiome DNA
Molekularanalytische in-vitro-diagnostische Verfahren - Spezifikationen für
präanalytische Prozesse für menschliche Proben - Isolierte Mikrobiom-DNA
Analyses moléculaires de diagnostic in vitro - Spécifications relatives aux processus
préanalytiques pour les échantillons humains - ADN du microbiote isolé
Ta slovenski standard je istoveten z: FprCEN/TS 17626
ICS:
11.100.10 Diagnostični preskusni In vitro diagnostic test
sistemi in vitro systems
kSIST-TS FprCEN/TS 17626:2021 en,fr,de
2003-01.Slovenski inštitut za standardizacijo. Razmnoževanje celote ali delov tega standarda ni dovoljeno.
---------------------- Page: 1 ----------------------
kSIST-TS FprCEN/TS 17626:2021
---------------------- Page: 2 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FINAL DRAFT
TECHNICAL SPECIFICATION
FprCEN/TS 17626
SPÉCIFICATION TECHNIQUE
TECHNISCHE SPEZIFIKATION
November 2020
ICS 11.100.01
English Version
Molecular in vitro diagnostic examinations - Specifications
for pre-examination processes for human specimen -
Isolated microbiome DNA
Analyses moléculaires de diagnostic in vitro - Molekularanalytische in-vitro-diagnostische Verfahren
Spécifications relatives aux processus préanalytiques - Spezifikationen für präanalytische Prozesse für
pour les échantillons humains - ADN du microbiote menschliche Proben - Isolierte Mikrobiom-DNA
isolé
This draft Technical Specification is submitted to CEN members for Vote. It has been drawn up by the Technical Committee
CEN/TC 140.
CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway,
Poland, Portugal, Republic of North Macedonia, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and
United Kingdom.
Recipients of this draft are invited to submit, with their comments, notification of any relevant patent rights of which they are
aware and to provide supporting documentation.
Warning : This document is not a Technical Specification. It is distributed for review and comments. It is subject to change
without notice and shall not be referred to as a Technical Specification.
EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG
CEN-CENELEC Management Centre: Rue de la Science 23, B-1040 Brussels
© 2020 CEN All rights of exploitation in any form and by any means reserved Ref. No. FprCEN/TS 17626:2020 E
worldwide for CEN national Members.
---------------------- Page: 3 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
Contents Page
European foreword . 4
Introduction . 5
1 Scope . 6
2 Normative references . 6
3 Terms and definitions . 6
4 General considerations . 11
5 Outside the laboratory . 12
5.1 Specimen collection . 12
5.1.1 General . 12
5.1.2 Information about the patient/specimen donor . 13
5.1.3 Specific information about the patient/specimen donor for specimens from gastro-
intestinal tract . 13
5.1.4 Selection of specimen collection method and device(s) . 14
5.1.5 Specimen collection from the patient/specimen donor and specimen stabilization. 16
5.2 Specimen storage and transport . 18
5.2.1 General . 18
5.2.2 Using collection devices with stabilizers . 18
5.2.3 Using collection devices without stabilizers . 19
6 Inside the laboratory . 20
6.1 Specimen reception . 20
6.2 Processing of specimens . 20
6.3 Specimen storage before microbiome DNA isolation . 21
6.4 Isolation of microbiome DNA . 21
6.4.1 General . 21
6.4.2 Using a commercial kit . 22
6.4.3 Using a laboratory developed procedure . 22
6.5 Quantity and quality assessment of isolated microbiome DNA . 23
6.5.1 General . 23
6.5.2 Quantity assessment . 23
6.5.3 Quality assessment . 23
6.6 Storage of isolated microbiome DNA . 24
6.6.1 General . 24
6.6.2 Microbiome DNA isolated using a commercial kit . 24
6.6.3 Microbiome DNA isolated using a laboratory developed procedure . 24
Annex A (informative) Impact of various pre-analytical variables on microbiome DNA
quantity, quality and profile . 25
A.1 Introduction . 25
A.2 Result - Impact of specimen stabilization method on isolated microbiome DNA
quantity . 25
A.2.1 General . 25
A.2.2 Method . 25
A.2.3 Result/conclusion . 26
2
---------------------- Page: 4 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
A.3 Result – Impact of specimen to stabilizer mass/volume ratio on isolated microbiome
DNA quantity and quality. 27
A.3.1 General . 27
A.3.2 Method . 27
A.3.3 Result/conclusion . 27
A.4 Result – Impact of different microbiome DNA isolation methods on microbiome DNA
profile. 28
A.4.1 General . 28
A.4.2 Method . 28
A.4.3 Result/conclusion . 29
A.5 Results - Impact of stabilization status and storage of collected specimens/samples
on microbiome DNA profile . 30
A.5.1 General . 30
A.5.2 Method . 30
A.5.3 Result/conclusion . 31
Annex B (informative) Importance of using an in-process quality control material . 32
B.1 Introduction . 32
B.2 Results . 32
B.2.1 General . 32
B.2.2 Method . 32
B.2.3 Result . 34
B.3 Conclusions . 34
Bibliography . 35
3
---------------------- Page: 5 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
European foreword
This document (FprCEN/TS 17626:2020) has been prepared by Technical Committee CEN/TC 140 “In
vitro diagnostic medical devices”, the secretariat of which is held by DIN.
This document is currently submitted to the Vote on TS.
4
---------------------- Page: 6 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
Introduction
Molecular in vitro diagnostics has enabled significant progress in medicine. Further progress is
expected using new technologies analysing the microbiome (e.g. bacteria, fungi, viruses, yeasts,
archaea) in human specimens.
The human microbiome has come into focus in many medical disciplines such as gastroenterology,
dermatology, or gynaecology as a potential biomarker for diagnosis and management of diseases, and
even as a therapeutic agent. Technologies analysing microbiome DNA such as shotgun metagenome or
amplicon-based sequencing (e.g. 16S or 18S rRNA gene sequencing) have accelerated this process and
are being increasingly performed in research and clinical practice.
However, the human microbiome profile can change drastically during the pre-examination process,
which includes the specimen collection, transport, storage, and processing. These changes can, for
example, be due to contamination of specimens with microbial cells or microbiome DNA from other
sources than the sampling site or due to undesired growth and/or stability of individual
microorganisms and viruses. Consequently, this makes the outcome from diagnostics or research
unreliable or even impossible because the subsequent examination might not determine the real
situation in the patient but an artificial profile generated during the pre-examination processes.
Therefore, special measures have to be taken to secure the stability of the microbiome profile.
Specimens for microbiome analysis are often collected by donors/patients. Therefore, dedicated
measures are needed for informing donors/patients about and preparing them for the collection,
storage and transport of specimens, and to check the compliance with the instructions, in order to
reduce specimen variability.
In addition, isolation of microbiome DNA, which is representative in composition of the in vivo
microbiome of the respective body site, is critical. This can be especially challenging e.g. due to different
lysis requirements of the microorganisms (e.g. Gram-negative versus Gram-positive bacteria, or versus
fungi) as well as inhibitory compounds (e.g. PCR inhibitors) in the specimen, which can impact the
examination if not removed during the DNA isolation. The presence of high amounts of human host
DNA, in addition to DNA introduced by reagents such as remnant plasmid DNA from generation of
recombinant enzymes and/or DNA isolation kits, can further impact the examination result.
Therefore, standardization of the entire pre-examination workflow from specimen collection to the
microbiome DNA examination is needed.
Studies have been undertaken to determine the important influencing factors. This document draws
upon such work to codify and standardize the steps for microbiome DNA examination in what is
referred to as the pre-examination phase.
In this document, the following verbal forms are used:
— “shall” indicates a requirement;
— “should” indicates a recommendation;
— “may” indicates a permission;
— “can” indicates a possibility or a capability.
5
---------------------- Page: 7 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
1 Scope
This document gives requirements and recommendations for the pre-examination phase of human
specimens, such as stool, saliva, skin and urogenital specimens, intended for microbiome DNA
examination. The pre-examination phase includes but is not limited to specimen collection, handling,
transport, storage, processing, isolation of DNA, and documentation.
This document is applicable to molecular in vitro diagnostic examinations performed by medical
laboratories. It is also intended to be used by laboratory customers, in vitro diagnostics developers and
manufacturers, biobanks, institutions and commercial organizations performing biomedical research,
and regulatory authorities.
Different dedicated measures are taken for pre-examination processes for infectious disease
examination (e.g. targeted pathogen identification) and for microbiome DNA examination from tissue
(e.g. biopsies). These are outside of the scope of this document.
Different dedicated measures are taken for pre-examination processes for saliva for human genomic
DNA examination. These are not described in this document but are covered in CEN/TS 17305,
Molecular in vitro diagnostic examinations — Specifications for pre-examination processes for saliva —
Isolated DNA.
NOTE International, national or regional regulations or requirements can also apply to specific topics
covered in this document.
2 Normative references
The following documents are referred to in the text in such a way that some or all of their content
constitutes requirements of this document. For dated references, only the edition cited applies. For
undated references, the latest edition of the referenced document (including any amendments) applies.
EN ISO 15189, Medical laboratories - Requirements for quality and competence (ISO 15189:2012,
Corrected version 2014-08-15)
EN ISO 15190, Medical laboratories — Requirements for safety
ISO/TS 20658, Medical laboratories — Requirements for collection, transport, receipt, and handling of
samples
3 Terms and definitions
For the purposes of this document, the terms and definitions given in EN ISO 15189 and the following
ones apply.
ISO and IEC maintain terminological databases for use in standardization at the following addresses:
— ISO Online browsing platform: available at https://www.iso.org/obp
— IEC Electropedia: available at http://www.electropedia.org/
3.1
aliquot
portion of a larger amount of homogeneous material, assumed to be taken with negligible sampling
error
Note 1 to entry: The term is usually applied to fluids
6
---------------------- Page: 8 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
Note 2 to entry: The definition is derived from the Compendium of Chemical Terminology Gold Book.
International Union of Pure and Applied Chemistry. Version 2.3.3., 2014; the PAC, 1990,62,1193 (Nomenclature
for sampling in analytical chemistry (Recommendations 1990)) p. 1206; and the PAC, 1990,62,2167 (Glossary of
atmospheric chemistry terms (Recommendations 1990)) p. 2173
3.2
ambient temperature
unregulated temperature of the surrounding air
3.3
analyte
component represented in the name of a measurable quantity
[SOURCE: EN ISO 17511:2003]
3.4
analytical test performance
accuracy, precision, and sensitivity of a test to measure the analyte [3.3] of interest
Note 1 to entry: to entry: Other test performance characteristics such as robustness, repeatability can apply as
well.
3.5
deoxyribonucleic acid
DNA
polymer of deoxyribonucleotides occurring in a double-stranded (dsDNA) or single-stranded (ssDNA)
form
[SOURCE: EN ISO 22174:2005, 3.1.2]
3.6
deoxyribonuclease
DNase
enzyme that catalyzes the degradation of DNA [3.5] into smaller components
3.7
deviation
departure from an approved instruction, procedure and/or method
[SOURCE: EN ISO 15378:2017, 3.7.5 modified — The words “approved (3.7.1) standard operating
procedure (SOP) (3.7.10)” were replaced by “instruction, procedure and/or method”.]
3.8
diagnosis
identification of a health or disease state from its signs and/or symptoms, where the diagnostic process
can involve examinations [3.9] and tests for classification of an individual's condition into separate and
distinct categories or subclasses that allow medical decisions about treatment and prognosis to be
made
7
---------------------- Page: 9 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
3.9
examination
analytical test
set of operations with the objective of determining the value or characteristics of a property
Note 1 to entry: Processes (i.e. set of operations) that start with the isolated analyte [3.3] and include all kinds
of parameter testing or chemical manipulation for quantitative or qualitative examination.
[SOURCE: EN ISO 15189:2012, 3.7, modified — The term and definition are used here without the
original notes.]
3.10
examination manufacturer
analytical test manufacturer
entity that manufactures and/or produces the specific analytical test [3.9]
3.11
homogeneous
uniform in structure and composition
3.12
interfering substances
endogenous substances of a specimen [3.26]/sample [3.25] or exogenous substances (e.g. stabilization
reagent [3.28]) that can alter an examination result
3.13
laboratory developed procedure
modified commercially available in vitro diagnostic device or fully in house developed procedure
3.14
microbial biomass
measure of the mass (amount) of microbiome [3.15] in a specimen [3.26]/sample [3.25]
3.15
microbiome, human
entire community of all commensal, symbiotic and pathogenic microorganisms [3.18] and viruses inside
and on specific human body sites in a particular environment/habitat
[SOURCE: [1][2][3][4]]
3.16
microbiome DNA
microbial DNA
DNA [3.5] of the microorganisms [3.18] and DNA viruses comprising the human microbiome [3.15]
3.17
microbiome DNA profile
microbial DNA profile
amounts of DNA molecules from the microbiome [3.15] that are present in a specimen [3.26]/sample
[3.25] and can be measured in the absence of any losses, inhibition or interference
8
---------------------- Page: 10 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
3.18
microorganisms
entity of microscopic size, encompassing bacteria, archaea, single celled eukaryotes (incl. fungi,
protozoa), and phages
[SOURCE: [1][2]]
3.19
nonconformity
non-fulfillment of a requirement
[SOURCE: EN ISO 9000:2015, 3.6.9, modified — Note 1 to entry deleted.]
3.20
pre-examination processes
pre-analytical workflow
pre-examination phase
pre-analytical phase
processes that start, in chronological order, from the clinician’s request and include the examination
request, preparation and identification of the patient, collection of the specimen(s) [3.24],
transportation to and within the medical laboratory, isolation of analytes [3.3], and ends when the
examination [3.9] begins
Note 1 to entry: The pre-examination phase includes preparative processes that influence the outcome of the
intended examination.
[SOURCE: EN ISO 15189:2012, 3.15, modified — An additional term has been added, the words
“primary sample(s)” were replaced by “specimen(s)” and more details have been included.]
3.21
primary collection device
tool specifically intended by a manufacturer to obtain or obtain and contain or obtain, contain and
preserve a specimen [3.26] from the donor/patient
[SOURCE: EN ISO 18113-1:2009, 3.55, Modified – Notes to entry have been deleted, “apparatus” has
been changed to “tool, “to obtain or obtain and contain” has been added, “for in vitro diagnostic
examination” has been deleted.]
3.22
secondary collection device
container into which the specimen [3.26] is transferred from or together with the primary collection
device [3.21]
3.23
proficiency test
evaluation of participant performance against pre-established criteria by means of inter-laboratory
comparisons
[SOURCE: ISO/IEC 17043:2010, 3.7, modified — Term and definition are used here without the original
notes to entry.]
9
---------------------- Page: 11 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
3.24
room temperature
for the purposes of this document, temperature in the range of 18 °C to 25 °C
Note 1 to entry: Local or national regulations can have different definitions.
3.25
sample
one or more parts taken from a specimen [3.26]
[SOURCE: EN ISO 15189:2012, 3.24, modified — The words “primary sample(s)” were replaced by
“specimen(s)” and the example has been omitted.]
3.26
specimen
primary sample
discrete portion of a body fluid, breath, hair, stool, or biological material mechanically taken off body or
organ surfaces (e.g. by swabs, brushes, tapes, spatulas or blades) or tissue taken for examination of one
or more quantities or properties assumed to apply for the whole
[SOURCE: EN ISO 15189:2012, 3.16, modified — NOTEs to entry have been omitted.]
3.27
stability
ability of a specimen [3.26]/sample [3.25] material, when stored under specified conditions, to
maintain a stated property value within specified limits for a specified period of time
Note 1 to entry: The analyte for the purpose of this document is DNA.
[SOURCE: ISO Guide 30:2015, 2.1.15, modified — The words “reference material” were replaced by
“specimen/sample material”.]
3.28
stabilizers
stabilization reagents
microbiome DNA stabilizers
compounds, solutions or mixtures that are designed to minimize changes of the microbiome DNA
profile [3.17] in a specimen [3.26] or sample [3.25] (by inhibition of undesired growth or decline of
microorganisms [3.18] and viruses, and/or of degradation and fragmentation of DNA [3.5])
3.29
storage
maintenance of biological material under conditions appropriate for intended use
3.30
validation
confirmation, throughout the provision of objective evidence, that the requirements for a specific
intended use or application have been fulfilled
Note 1 to entry: The term “validated” is used to designate the corresponding status.
[SOURCE: ISO 9000:2015, 3.8.13, modified — NOTE 1 and 3 have been omitted.]
10
---------------------- Page: 12 ----------------------
kSIST-TS FprCEN/TS 17626:2021
FprCEN/TS 17626:2020 (E)
3.31
verification
confirmation, through provision of objective evidence, that specified requirements have been fulfilled
Note 1 to entry: The term “verified” is used to designate the corresponding status.
[SOURCE: ISO 9000:2015, 3.8.12, modified — NOTE 1 and NOTE 2 have been omitted.]
Note 2 to entry: Confirmation can comprise activities such as:
— performing alternative calculations;
— comparing a new design specification with a similar proven design specification;
— undertaking tests and demonstrations; and
— reviewing documents prior to issue
3.32
workflow
series of activities necessary to complete a task
4 General considerations
For general statements on medical laboratory quality management systems and in particular on
specimen collection, reception and handling (including avoidance of cross contaminations) see
EN ISO 15189, EN ISO/IEC 17025 or EN ISO/IEC 17020. The requirements on laboratory equipment,
reagents, and consumables according to EN ISO 15189 shall be followed; EN ISO/IEC 17025 and
ISO/IEC 17020 can also apply.
All steps of the pre-examination, examination and post-examination processes (i.e. the entire workflow)
can influence the diagnosis or research study results.
Thus, this entire workflow shall be specified, verified and validated during the development of the
examination, including in vitro diagnostic (IVD) medical devices. This includes specifically all pre-
examination process steps such as the examination request, preparation and identification of the
patient, collection of the primary sample(s), transportation to and within the medical laboratory,
storage and isolation of analytes. This shall also include determination of and information on the
stability of the specimen within the timeframe between taking the specimen and its analysis and
storage conditions such as duration, temperature limits and freeze/thaw cycles.
The microbiome profile can change drastically during the pre-examination phase [5][6][27][28].
Microbiome composition and densities are influenced by lifestyle conditions [7], and treatment of the
sampling site prior to specimen collection, and strongly differ depending on the body site and disease
state. The microbiome also differs from individual to individual. Different collection methods can vary
in microbial biomass yield and extent of human DNA contamination [6][7][8]. Upon removal of
specimens from the body undesirable growth or decline of certain microorganisms/viruses and
degradation and fragmentation of DNA can occur without rapid specimen stabilization by microbiome
DNA stabilizers, freezing or immediate microbiome DNA isolation [5][6]. Also, different DNA isolation
methods, particularly the lysis step, can influence the DNA profile and quantity as different
microorganisms
...
Questions, Comments and Discussion
Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.